<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Hepatocellular Carcinoma - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "‚Ü≥ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Hepatocellular Carcinoma</span>
        </nav>

        <header class="page-header">
            <h1>Hepatocellular Carcinoma</h1>
            <div class="header-meta">
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0007256" target="_blank">
                        MONDO:0007256
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">liver carcinoma</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                Hepatocellular carcinoma (HCC) is the most common primary liver malignancy, typically arising in the setting of chronic liver disease and cirrhosis. Major risk factors include chronic hepatitis B or C infection, alcohol-related liver disease, and metabolic dysfunction-associated steatotic liver disease (MASLD/NAFLD). HCC pathogenesis involves multiple molecular pathways including WNT/beta-catenin, TP53, telomere maintenance, and chromatin remodeling. The combination of atezolizumab (anti-PD-L1) plus bevacizumab (anti-VEGF) has established immunotherapy as first-line treatment for advanced HCC, based on the IMbrave150 trial.
            </p>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Inheritance</div>
            </div>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">7</div>
                <div class="stat-label">Mechanisms</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#histopathology">
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Histopathology</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">7</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#genetic">
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Genes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">8</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#subtypes">
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Subtypes</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
            
        </div>

        <!-- Classifications -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üè∑</div>
                <h2 class="card-title">Classifications</h2>
            </div>
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">Harrison's Chapter</div>
                <div class="tag-list">
                    
                    <span class="tag tag-classification">cancer</span>
                    
                    <span class="tag tag-classification">solid tumor</span>
                    
                </div>
            </div>
            
            
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">ICD-O Morphology</div>
                <div class="tag-list">
                    <span class="tag tag-classification">Carcinoma</span>
                </div>
            </div>
            
            
            
            
        </div>
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        

        <!-- Subtypes -->
        
        <div class="card" id="subtypes">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">‚óÜ</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">4</span>
            </div>
            
            
            
                
                
                    
                
                
            
                
                
                
            
                
                
                
            
                
                
                
            
            
                
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Viral Hepatitis-Associated HCC
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">HCC arising in the context of chronic hepatitis B or C infection. HBV can be directly oncogenic through viral integration, while HCV promotes HCC primarily through cirrhosis and chronic inflammation.</div>
                    
                    
                    
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Alcohol-Related HCC
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">HCC arising in alcohol-related liver disease and cirrhosis. Associated with specific molecular features and generally presents at more advanced stage.</div>
                    
                    
                    
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        MASLD-Associated HCC
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">HCC arising in metabolic dysfunction-associated steatotic liver disease (formerly NAFLD/NASH). Increasingly common subtype that can occur even without cirrhosis. May have distinct immune microenvironment features affecting immunotherapy response.</div>
                    
                    
                    
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Fibrolamellar HCC
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Rare variant occurring in younger patients without cirrhosis. Characterized by DNAJB1-PRKACA fusion. Distinct clinical behavior and treatment considerations.</div>
                    
                    
                    
    
    
                </div>
                
            
        </div>
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">‚öô</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">7</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Chronic Liver Injury and Cirrhosis</div>
                
                <div class="item-desc">Most HCC arises in the context of chronic liver disease and cirrhosis. Persistent hepatocyte death and regeneration in an inflammatory environment promotes accumulation of genetic alterations. Cirrhosis itself is a premalignant condition with ongoing oxidative stress and genomic instability.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        hepatocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000182" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        liver
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0002107" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/41567639" target="_blank">PMID:41567639</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"HCC typically arises in patients with chronic liver disease, including hepatitis, cirrhosis, and non-alcoholic fatty liver diseases."</div>
                
                
                <div class="evidence-explanation">This abstract states that HCC commonly arises in chronic liver disease and cirrhosis, supporting the mechanism described.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Telomere Dysfunction and Genomic Instability</div>
                
                <div class="item-desc">Chronic hepatocyte proliferation leads to telomere shortening, causing genomic instability. TERT promoter mutations, which are the most common HCC mutations, reactivate telomerase to enable unlimited replication. This creates a checkpoint bypass allowing survival of genetically unstable cells.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        telomere maintenance
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0000723" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚ö† ABNORMAL
    </span>
    
    
                    
                </div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Accumulation of Driver Mutations</div>
                
                <div class="item-desc">Multiple driver genes are recurrently mutated in HCC, including TERT promoter (60%), TP53 (30%), CTNNB1 (30%), AXIN1 (10%), and ARID1A (10%). These mutations affect telomere maintenance, cell cycle control, WNT signaling, and chromatin remodeling.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        DNA repair
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006281" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üì DECREASED
    </span>
    
    
                    
                </div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">WNT/Beta-Catenin Pathway Activation</div>
                
                <div class="item-desc">Activating mutations in CTNNB1 (beta-catenin) or inactivating mutations in AXIN1 lead to constitutive WNT pathway activation. This drives cell proliferation and is associated with a distinct molecular subclass of HCC with specific clinical features including cholestasis and immune exclusion.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Wnt signaling pathway
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0016055" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üë INCREASED
    </span>
    
    
                    
                </div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">TP53 Pathway Inactivation</div>
                
                <div class="item-desc">TP53 mutations are common in HCC, particularly in HBV-associated and aflatoxin-associated tumors. Loss of p53 function removes a critical checkpoint, allowing survival of cells with DNA damage and promoting genomic instability.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        apoptotic process
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006915" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üì DECREASED
    </span>
    
    
                    
                </div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Enhanced Hepatocyte Proliferation</div>
                
                <div class="item-desc">Combined effects of telomerase reactivation, cell cycle checkpoint loss, and mitogenic signaling drive uncontrolled hepatocyte proliferation and tumor growth.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        cell population proliferation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0008283" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üë INCREASED
    </span>
    
    
                    
                </div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Angiogenesis and VEGF Signaling</div>
                
                <div class="item-desc">HCC is a highly vascular tumor dependent on angiogenesis. VEGF signaling promotes new blood vessel formation supplying the tumor. VEGF also has immunosuppressive effects, contributing to the immune-excluded microenvironment. This provides the rationale for anti-VEGF therapy in combination with immunotherapy.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        angiogenesis
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0001525" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    <span class="tag tag-modifier">
        ‚Üë INCREASED
    </span>
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19637355" target="_blank">PMID:19637355</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Hepatocellular carcinoma (HCC) is a highly vascular tumor, and angiogenesis is believed to play a considerable role in its development and progression."</div>
                
                
                <div class="evidence-explanation">Abstract notes HCC is highly vascular and angiogenesis plays a major role, supporting this mechanism.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        
        <div class="card" id="histopathology">
            <div class="card-header">
                <div class="card-icon" style="background: #ffedd5; color: #c2410c;">‚ú∂</div>
                <h2 class="card-title">Histopathology</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box histopathology-box">
                <div class="item-name">
                    Hepatocellular Carcinoma
                    
                    <span class="histopathology-freq">VERY_FREQUENT</span>
                    
                </div>
                
                <div class="item-desc">Hepatocellular carcinoma is the most common primary liver malignancy.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27785449" target="_blank">PMID:27785449</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Hepatocellular carcinoma (HCC) is the most common primary liver malignancy"</div>
                
                
                <div class="evidence-explanation">Abstract states that HCC is the most common primary liver malignancy.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">‚¨°</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph LR
    WNT_Beta_Catenin_Pathway_Activation[&#34;WNT/Beta-Catenin Pathway Activation&#34;]
    Chronic_Liver_Injury_and_Cirrhosis[&#34;Chronic Liver Injury and Cirrhosis&#34;]
    Accumulation_of_Driver_Mutations[&#34;Accumulation of Driver Mutations&#34;]
    Telomere_Dysfunction_and_Genomic_Instability[&#34;Telomere Dysfunction and Genomic Instability&#34;]
    Enhanced_Hepatocyte_Proliferation[&#34;Enhanced Hepatocyte Proliferation&#34;]

    Chronic_Liver_Injury_and_Cirrhosis --&gt; Telomere_Dysfunction_and_Genomic_Instability
    Chronic_Liver_Injury_and_Cirrhosis --&gt; Accumulation_of_Driver_Mutations
    Telomere_Dysfunction_and_Genomic_Instability --&gt; WNT_Beta_Catenin_Pathway_Activation
    WNT_Beta_Catenin_Pathway_Activation --&gt; Enhanced_Hepatocyte_Proliferation

    style WNT_Beta_Catenin_Pathway_Activation fill:#dbeafe
    style Chronic_Liver_Injury_and_Cirrhosis fill:#dbeafe
    style Accumulation_of_Driver_Mutations fill:#dbeafe
    style Telomere_Dysfunction_and_Genomic_Instability fill:#dbeafe
    style Enhanced_Hepatocyte_Proliferation fill:#dbeafe</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">‚óè</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">7</span>
            </div>
            
            
            <div class="pheno-toc">
                
                <a class="pheno-toc-pill" data-target="pheno-cat-1">Digestive<span class="pill-count">(4)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-2">Constitutional<span class="pill-count">(2)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-3">Growth<span class="pill-count">(1)</span></a>
                
                <button class="pheno-toggle-all" id="phenoToggleAll">Expand all</button>
            </div>
            
            
            <details class="phenotype-category-group" id="pheno-cat-1">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Digestive
                    <span class="cat-count">4</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Hepatomegaly
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002240" target="_blank">
                                Hepatomegaly
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002240)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Ascites
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001541" target="_blank">
                                Ascites
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001541)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Jaundice
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000952" target="_blank">
                                Jaundice
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000952)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Nausea
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002018" target="_blank">
                                Nausea
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002018)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-2">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Constitutional
                    <span class="cat-count">2</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Abdominal Pain
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002027" target="_blank">
                                Abdominal pain
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002027)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Fatigue
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0012378" target="_blank">
                                Fatigue
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0012378)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-3">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Growth
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Weight Loss
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001824" target="_blank">
                                Weight loss
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001824)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
            </details>
            
            <script>
            (function() {
                // TOC pill click: expand target group and scroll to it
                document.querySelectorAll('.pheno-toc-pill').forEach(function(pill) {
                    pill.addEventListener('click', function() {
                        var target = document.getElementById(pill.dataset.target);
                        if (target) {
                            target.open = true;
                            target.scrollIntoView({behavior: 'smooth', block: 'start'});
                        }
                    });
                });
                // Expand/collapse all toggle
                var btn = document.getElementById('phenoToggleAll');
                if (btn) {
                    btn.addEventListener('click', function() {
                        var groups = document.querySelectorAll('.phenotype-category-group');
                        var anyOpen = Array.from(groups).some(function(g) { return g.open; });
                        groups.forEach(function(g) { g.open = !anyOpen; });
                        btn.textContent = anyOpen ? 'Expand all' : 'Collapse all';
                    });
                }
            })();
            </script>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card" id="genetic">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">üß¨</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TERT Promoter
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Somatic Activating Mutation)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TP53
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Somatic Loss of Function)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    CTNNB1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Somatic Activating Mutation)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    AXIN1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Somatic Loss of Function)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    ARID1A
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Somatic Loss of Function)</span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">üíä</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">8</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Atezolizumab plus Bevacizumab
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">First-line standard of care for unresectable HCC based on IMbrave150 trial. Anti-PD-L1 (atezolizumab) combined with anti-VEGF (bevacizumab) demonstrated superior overall survival compared to sorafenib. Requires adequate liver function (Child-Pugh A) and no high-risk varices.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39687036" target="_blank">PMID:39687036</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Atezolizumab plus bevacizumab significantly improved overall survival (OS) and progression-free survival (PFS) versus sorafenib"</div>
                
                
                <div class="evidence-explanation">IMbrave150 abstract reports improved overall and progression-free survival with atezolizumab plus bevacizumab versus sorafenib.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Durvalumab plus Tremelimumab
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Alternative first-line immunotherapy option. HIMALAYA trial demonstrated durvalumab (anti-PD-L1) with single priming dose of tremelimumab (anti-CTLA-4) improves survival compared to sorafenib. Option for patients who cannot receive bevacizumab.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Sorafenib
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Multi-kinase inhibitor targeting RAF, VEGFR, and PDGFR. Was first systemic therapy to improve survival in HCC. Now used in second line or when immunotherapy is contraindicated.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Lenvatinib
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Multi-kinase inhibitor with activity against VEGFR, FGFR, PDGFR, RET, and KIT. Non-inferior to sorafenib in first line. Alternative when immunotherapy not appropriate.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Surgical Resection
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000004" target="_blank">
                            MAXO:0000004
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Potentially curative for early-stage HCC in patients with preserved liver function (Child-Pugh A). Limited by underlying cirrhosis in many patients. Requires adequate future liver remnant.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Liver Transplantation
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0010039" target="_blank">
                            MAXO:0010039
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Potentially curative treatment that addresses both tumor and underlying cirrhosis. Milan criteria (single tumor 5 cm or less or up to 3 tumors each 3 cm or less, no vascular invasion, no metastases) guide patient selection. Limited by organ availability.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Transarterial Chemoembolization (TACE)
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000647" target="_blank">
                            MAXO:0000647
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Locoregional therapy delivering chemotherapy directly to tumor via hepatic artery followed by embolization. Standard for intermediate-stage HCC (BCLC-B). Can be used as bridge to transplant or with systemic therapy.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Radiofrequency/Microwave Ablation
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000452" target="_blank">
                            MAXO:0000452
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Thermal ablation for small tumors (typically less than 3 cm). Effective alternative to resection for early-stage HCC, particularly in patients with limited liver function.</div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üî¨</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Alpha-Fetoprotein (AFP)
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Liver Function Tests
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    PIVKA-II (DCP)
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Hepatocellular Carcinoma
description: &gt;-
  Hepatocellular carcinoma (HCC) is the most common primary liver malignancy, typically arising
  in the setting of chronic liver disease and cirrhosis. Major risk factors include chronic
  hepatitis B or C infection, alcohol-related liver disease, and metabolic dysfunction-associated
  steatotic liver disease (MASLD/NAFLD). HCC pathogenesis involves multiple molecular pathways
  including WNT/beta-catenin, TP53, telomere maintenance, and chromatin remodeling. The
  combination of atezolizumab (anti-PD-L1) plus bevacizumab (anti-VEGF) has established
  immunotherapy as first-line treatment for advanced HCC, based on the IMbrave150 trial.
categories:
- Gastrointestinal Cancer
- Hepatobiliary Cancer
- Liver Cancer
parents:
- liver carcinoma
has_subtypes:
- name: Viral Hepatitis-Associated HCC
  description: &gt;-
    HCC arising in the context of chronic hepatitis B or C infection. HBV can be directly
    oncogenic through viral integration, while HCV promotes HCC primarily through cirrhosis
    and chronic inflammation.
- name: Alcohol-Related HCC
  description: &gt;-
    HCC arising in alcohol-related liver disease and cirrhosis. Associated with specific
    molecular features and generally presents at more advanced stage.
- name: MASLD-Associated HCC
  description: &gt;-
    HCC arising in metabolic dysfunction-associated steatotic liver disease (formerly NAFLD/NASH).
    Increasingly common subtype that can occur even without cirrhosis. May have distinct
    immune microenvironment features affecting immunotherapy response.
- name: Fibrolamellar HCC
  description: &gt;-
    Rare variant occurring in younger patients without cirrhosis. Characterized by DNAJB1-PRKACA
    fusion. Distinct clinical behavior and treatment considerations.
pathophysiology:
- name: Chronic Liver Injury and Cirrhosis
  description: &gt;-
    Most HCC arises in the context of chronic liver disease and cirrhosis. Persistent
    hepatocyte death and regeneration in an inflammatory environment promotes accumulation
    of genetic alterations. Cirrhosis itself is a premalignant condition with ongoing
    oxidative stress and genomic instability.
  evidence:
  - reference: PMID:41567639
    supports: SUPPORT
    snippet: HCC typically arises in patients with chronic liver disease, including hepatitis, cirrhosis, and 
      non-alcoholic fatty liver diseases.
    explanation: This abstract states that HCC commonly arises in chronic liver disease and cirrhosis, supporting the 
      mechanism described.
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  downstream:
  - target: Telomere Dysfunction and Genomic Instability
    description: Repeated hepatocyte division leads to telomere shortening
  - target: Accumulation of Driver Mutations
    description: Chronic regeneration promotes mutation accumulation
- name: Telomere Dysfunction and Genomic Instability
  description: &gt;-
    Chronic hepatocyte proliferation leads to telomere shortening, causing genomic instability.
    TERT promoter mutations, which are the most common HCC mutations, reactivate telomerase
    to enable unlimited replication. This creates a checkpoint bypass allowing survival
    of genetically unstable cells.
  biological_processes:
  - preferred_term: telomere maintenance
    modifier: ABNORMAL
    term:
      id: GO:0000723
      label: telomere maintenance
  downstream:
  - target: WNT/Beta-Catenin Pathway Activation
    description: Genomic instability promotes acquisition of pathway-activating mutations
- name: Accumulation of Driver Mutations
  description: &gt;-
    Multiple driver genes are recurrently mutated in HCC, including TERT promoter (60%),
    TP53 (30%), CTNNB1 (30%), AXIN1 (10%), and ARID1A (10%). These mutations affect
    telomere maintenance, cell cycle control, WNT signaling, and chromatin remodeling.
  biological_processes:
  - preferred_term: DNA repair
    modifier: DECREASED
    term:
      id: GO:0006281
      label: DNA repair
- name: WNT/Beta-Catenin Pathway Activation
  description: &gt;-
    Activating mutations in CTNNB1 (beta-catenin) or inactivating mutations in AXIN1
    lead to constitutive WNT pathway activation. This drives cell proliferation and is
    associated with a distinct molecular subclass of HCC with specific clinical features
    including cholestasis and immune exclusion.
  biological_processes:
  - preferred_term: Wnt signaling pathway
    modifier: INCREASED
    term:
      id: GO:0016055
      label: Wnt signaling pathway
  downstream:
  - target: Enhanced Hepatocyte Proliferation
    description: WNT signaling drives cell proliferation and stemness
- name: TP53 Pathway Inactivation
  description: &gt;-
    TP53 mutations are common in HCC, particularly in HBV-associated and aflatoxin-associated
    tumors. Loss of p53 function removes a critical checkpoint, allowing survival of cells
    with DNA damage and promoting genomic instability.
  biological_processes:
  - preferred_term: apoptotic process
    modifier: DECREASED
    term:
      id: GO:0006915
      label: apoptotic process
- name: Enhanced Hepatocyte Proliferation
  description: &gt;-
    Combined effects of telomerase reactivation, cell cycle checkpoint loss, and
    mitogenic signaling drive uncontrolled hepatocyte proliferation and tumor growth.
  biological_processes:
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
- name: Angiogenesis and VEGF Signaling
  description: &gt;-
    HCC is a highly vascular tumor dependent on angiogenesis. VEGF signaling promotes
    new blood vessel formation supplying the tumor. VEGF also has immunosuppressive
    effects, contributing to the immune-excluded microenvironment. This provides the
    rationale for anti-VEGF therapy in combination with immunotherapy.
  evidence:
  - reference: PMID:19637355
    supports: SUPPORT
    snippet: &#34;Hepatocellular carcinoma (HCC) is a highly vascular tumor, and angiogenesis is believed to play a considerable role in its development and progression.&#34;
    explanation: &#34;Abstract notes HCC is highly vascular and angiogenesis plays a major role, supporting this mechanism.&#34;
  biological_processes:
  - preferred_term: angiogenesis
    modifier: INCREASED
    term:
      id: GO:0001525
      label: angiogenesis
histopathology:
- name: Hepatocellular Carcinoma
  finding_term:
    preferred_term: Hepatocellular Carcinoma
    term:
      id: NCIT:C3099
      label: Hepatocellular Carcinoma
  frequency: VERY_FREQUENT
  description: Hepatocellular carcinoma is the most common primary liver malignancy.
  evidence:
  - reference: PMID:27785449
    supports: SUPPORT
    snippet: &#34;Hepatocellular carcinoma (HCC) is the most common primary liver malignancy&#34;
    explanation: Abstract states that HCC is the most common primary liver malignancy.

phenotypes:
- category: Hepatic
  name: Hepatomegaly
  frequency: FREQUENT
  description: &gt;-
    Liver enlargement from tumor mass. May be palpable as a hard, irregular mass in the
    right upper quadrant.
  phenotype_term:
    preferred_term: Hepatomegaly
    term:
      id: HP:0002240
      label: Hepatomegaly
- category: Hepatic
  name: Ascites
  frequency: FREQUENT
  description: &gt;-
    Abdominal fluid accumulation from portal hypertension (cirrhosis) and/or tumor-related
    factors. Presence indicates advanced disease and decompensated liver function.
  phenotype_term:
    preferred_term: Ascites
    term:
      id: HP:0001541
      label: Ascites
- category: Hepatic
  name: Jaundice
  frequency: OCCASIONAL
  description: &gt;-
    Yellowing of skin and sclera from elevated bilirubin. May result from biliary obstruction
    by tumor, hepatic failure, or diffuse tumor infiltration.
  phenotype_term:
    preferred_term: Jaundice
    term:
      id: HP:0000952
      label: Jaundice
- category: Gastrointestinal
  name: Abdominal Pain
  frequency: FREQUENT
  description: &gt;-
    Right upper quadrant pain or discomfort from liver capsule distension or tumor growth.
    Sudden severe pain may indicate tumor rupture.
  phenotype_term:
    preferred_term: Abdominal pain
    term:
      id: HP:0002027
      label: Abdominal pain
- category: Constitutional
  name: Weight Loss
  frequency: VERY_FREQUENT
  description: &gt;-
    Unintentional weight loss is common in HCC due to cancer cachexia, reduced oral intake,
    and altered metabolism.
  phenotype_term:
    preferred_term: Weight loss
    term:
      id: HP:0001824
      label: Weight loss
- category: Constitutional
  name: Fatigue
  frequency: VERY_FREQUENT
  description: &gt;-
    Fatigue from liver dysfunction, anemia, and cancer-related factors.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
- category: Gastrointestinal
  name: Nausea
  frequency: FREQUENT
  description: &gt;-
    Nausea and anorexia from liver dysfunction and advanced disease.
  phenotype_term:
    preferred_term: Nausea
    term:
      id: HP:0002018
      label: Nausea
biochemical:
- name: Alpha-Fetoprotein (AFP)
  notes: &gt;-
    Serum AFP is elevated in approximately 60% of HCC cases. Levels greater than 400 ng/mL
    are highly specific for HCC in the setting of cirrhosis. Used for diagnosis (with
    imaging) and monitoring treatment response. AFP-L3 fraction improves specificity.
- name: Liver Function Tests
  notes: &gt;-
    Elevated transaminases, alkaline phosphatase, and bilirubin may occur. Pattern depends
    on underlying liver disease and tumor burden. Child-Pugh score assesses hepatic reserve
    and guides treatment decisions.
- name: PIVKA-II (DCP)
  notes: &gt;-
    Des-gamma-carboxy prothrombin is an alternative biomarker to AFP. May be elevated
    when AFP is normal. Useful in combination with AFP for surveillance and diagnosis.
genetic:
- name: TERT Promoter
  association: Somatic Activating Mutation
  notes: &gt;-
    TERT promoter mutations (C228T, C250T) are the most common genetic alterations in HCC,
    present in approximately 60% of cases. These mutations create binding sites for ETS
    transcription factors, reactivating telomerase expression and enabling unlimited
    cell division.
- name: TP53
  association: Somatic Loss of Function
  notes: &gt;-
    TP53 mutations occur in approximately 30% of HCC, enriched in HBV-associated and
    aflatoxin-associated tumors. The R249S hotspot mutation is specifically associated
    with aflatoxin B1 exposure.
- name: CTNNB1
  association: Somatic Activating Mutation
  notes: &gt;-
    CTNNB1 (beta-catenin) mutations occur in approximately 30% of HCC, causing constitutive
    WNT pathway activation. Associated with distinct clinical features including
    cholestasis and immune exclusion, potentially affecting immunotherapy response.
- name: AXIN1
  association: Somatic Loss of Function
  notes: &gt;-
    AXIN1 inactivating mutations occur in approximately 10% of HCC, also activating
    WNT signaling. AXIN1 and CTNNB1 mutations are typically mutually exclusive.
- name: ARID1A
  association: Somatic Loss of Function
  notes: &gt;-
    ARID1A mutations affect chromatin remodeling and occur in approximately 10% of HCC.
    Part of the SWI/SNF complex alterations seen across multiple cancer types.
treatments:
- name: Atezolizumab plus Bevacizumab
  description: &gt;-
    First-line standard of care for unresectable HCC based on IMbrave150 trial. Anti-PD-L1
    (atezolizumab) combined with anti-VEGF (bevacizumab) demonstrated superior overall
    survival compared to sorafenib. Requires adequate liver function (Child-Pugh A) and
    no high-risk varices.
  evidence:
  - reference: PMID:39687036
    supports: SUPPORT
    snippet: &#34;Atezolizumab plus bevacizumab significantly improved overall survival (OS) and progression-free survival (PFS) versus sorafenib&#34;
    explanation: &#34;IMbrave150 abstract reports improved overall and progression-free survival with atezolizumab plus bevacizumab versus sorafenib.&#34;
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Durvalumab plus Tremelimumab
  description: &gt;-
    Alternative first-line immunotherapy option. HIMALAYA trial demonstrated durvalumab
    (anti-PD-L1) with single priming dose of tremelimumab (anti-CTLA-4) improves survival
    compared to sorafenib. Option for patients who cannot receive bevacizumab.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Sorafenib
  description: &gt;-
    Multi-kinase inhibitor targeting RAF, VEGFR, and PDGFR. Was first systemic therapy
    to improve survival in HCC. Now used in second line or when immunotherapy is
    contraindicated.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Lenvatinib
  description: &gt;-
    Multi-kinase inhibitor with activity against VEGFR, FGFR, PDGFR, RET, and KIT.
    Non-inferior to sorafenib in first line. Alternative when immunotherapy not appropriate.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Surgical Resection
  description: &gt;-
    Potentially curative for early-stage HCC in patients with preserved liver function
    (Child-Pugh A). Limited by underlying cirrhosis in many patients. Requires adequate
    future liver remnant.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
- name: Liver Transplantation
  description: &gt;-
    Potentially curative treatment that addresses both tumor and underlying cirrhosis.
    Milan criteria (single tumor 5 cm or less or up to 3 tumors each 3 cm or less, no
    vascular invasion, no metastases) guide patient selection. Limited by organ availability.
  treatment_term:
    preferred_term: organ transplantation
    term:
      id: MAXO:0010039
      label: organ transplantation
- name: Transarterial Chemoembolization (TACE)
  description: &gt;-
    Locoregional therapy delivering chemotherapy directly to tumor via hepatic artery
    followed by embolization. Standard for intermediate-stage HCC (BCLC-B). Can be used
    as bridge to transplant or with systemic therapy.
  treatment_term:
    preferred_term: chemotherapy
    term:
      id: MAXO:0000647
      label: chemotherapy
- name: Radiofrequency/Microwave Ablation
  description: &gt;-
    Thermal ablation for small tumors (typically less than 3 cm). Effective alternative
    to resection for early-stage HCC, particularly in patients with limited liver function.
  treatment_term:
    preferred_term: ablation therapy
    term:
      id: MAXO:0000452
      label: ablation therapy
disease_term:
  preferred_term: hepatocellular carcinoma
  term:
    id: MONDO:0007256
    label: hepatocellular carcinoma

classifications:
  icdo_morphology:
    classification_value: Carcinoma
  harrisons_chapter:
  - classification_value: cancer
  - classification_value: solid tumor
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Hepatocellular_Carcinoma.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
</body>
</html>